Please wait

Exhibit 107

CALCULATION OF FILING FEE TABLES

Form S-3

(Form Type)

PMV Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                         
    

Security

Type

  

Security

Class

Title

   Fee
Calculation
or Carry
Forward
Rule		   Amount
Registered
   Proposed
Maximum
Offering
Price
per Unit		   Maximum
Aggregate
Offering
Price		  

Fee

Rate

   Amount of
Registration
Fee		   Carry
Forward
Form
Type		   Carry
Forward
File
Number		   Carry
Forward
Initial
Effective
Date		   Filing Fee
Previously
Paid in
Connection
with
Unsold
Securities
to be
Carried
Forward
 
Newly Registered Securities
                         
Fees to Be Paid   Equity   Common Stock, par value $0.00001 per share     (1)(2)   (3)   (3)     —          
                         
    Equity   Preferred Stock, par value $0.00001 per share     (1)(2)   (3)   (3)     —          
                         
    Debt   Debt Securities     (1)(2)   (3)   (3)     —          
                         
    Other   Warrants     (1)(2)   (3)   (3)     —          
                         
    Other   Subscription Rights     (1)(2)   (3)   (3)     —          
                         
    Other   Purchase Contracts     (1)(2)   (3)   (3)     —          
                         
    Other   Units(4)     (1)(2)   (3)   (3)     —          
                         
    Unallocated (Universal) Shelf   —   457(o)   (1)(2)   (3)   $200,000,000(3)   $153.10 per $1,000,000   $30,620          
                   
    Total Offering Amounts      $200,000,000     $30,620          
                   
    Total Fee Previously Paid          —          
                   
    Total Fee Offsets          $30,620          
                   
    Net Fee Due                —                

Table 2: Fee Offset Claims and Sources

                       
    

Registrant

or Filer

Name

  

Form

or

Filing

Type

  

File

Number

   Initial
Filing
Date		   Filing
Date		  

Fee

Offset
Claimed

  

Security

Type
Associated
with Fee
Offset
Claimed

   Security
Title
Associated
with Fee
Offset
Claimed		   Unsold
Securities
Associated
with Fee
Offset
Claimed		  

Unsold

Aggregate

Offering

Amount

Associated

with Fee

Offset

Claimed

  

Fee

Paid

with

Fee

Offset

Source

 
Rule 457(p)
                       

Fee Offset

Claims

   PMV Pharmaceuticals, Inc.   S-3ASR   333-260012   October 4, 2021     $8,580(5)   Equity   Common  Stock, par value $0.00001 per share   N/A   $113,792,846.40     
                       

Fee Offset

Sources

   PMV Pharmaceuticals, Inc.   S-3ASR   333-260012     October 4, 2021             $13,905
                       

Fee Offset

Claims

   PMV Pharmaceuticals, Inc.   POSASR    333-260012   March 1, 2023     $22,040(6)  

Unallocated (Universal)

Shelf

   —    N/A   $200,000,000    
                       

Fee Offset

Sources

   PMV Pharmaceuticals, Inc.   POSASR    333-260012       March 1, 2023                       $22,040
                                             
  (1)

The securities registered consists of up to $200,000,000 of an indeterminate number of (a) shares of common stock, (b) shares of preferred stock, (c) debt securities, (d) warrants to purchase common stock, preferred stock or debt securities of the registrant, (e) subscription rights to purchase common stock, preferred stock, debt securities, warrants or units consisting of some or all of these securities of the registrant, (f) purchase contracts, and (g) units consisting of some or all of these securities, as may be sold from time to time by the registrant. There are also being registered hereunder an indeterminate number of shares of common stock and preferred stock as shall be issuable upon conversion, exchange or exercise of any securities that provide for such issuance.

 

 

  (2)

Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, this registration statement shall also cover any additional shares of the registrant’s securities that become issuable by reason of any share splits, share dividends or similar transactions.

 

 

  (3)

The proposed maximum per security and aggregate offering prices per class of securities will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security. Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of other securities, or that are issued in units.

 

 

  (4)

Consisting of some or all of the securities listed above, in any combination, including common stock, preferred stock, debt securities, warrants, purchase contracts and subscription rights.

 

 

  (5)

On October 4, 2021, the registrant filed a Registration Statement on Form S-3ASR (File No. 333-260012) (the “Prior Registration Statement”), including a sales agreement prospectus supplement (the “Prior ATM Prospectus Supplement”) covering the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $150,000,000 of the registrant’s common stock. $36,207,153.60 of securities were sold pursuant to the Prior ATM Prospectus Supplement. The Prior Registration Statement expired on October 4, 2024, and therefore all offerings thereunder have been completed or terminated. As a result, the registrant has $113,792,846.40 of unsold securities and $10,548 in unused filing fees associated with the Prior ATM Prospectus Supplement. In accordance with Rule 457(p) under the Securities Act, the Registrant is using a portion of the unused filing fees associated with the Prior ATM Prospectus Supplement to offset the filing fee payable in connection with this filing.

 

  (6)

On March 1, 2023, the registrant filed a Post-Effective Amendment No. 1 to the Prior Registration Statement (the “Prior Post-Effective Amendment”) for the purpose of including disclosure required for a registrant other than a well-known seasoned issuer, identifying the securities being registered, registering up to $200,000,000 of the registrant’s common stock, preferred stock, debt securities, warrants, subscription rights, purchase contracts and units and paying the associated filing fee. Of the $200,000,000 of securities registered with the Prior Post-Effective Amendment, none have been sold. The Prior Registration Statement expired on October 4, 2024, and therefore all offerings thereunder have been completed or terminated. As a result, the registrant has $200,000,000 of unsold securities and $22,040 in unused filing fees associated with the Prior Post-Effective Amendment. In accordance with Rule 457(p) under the Securities Act, the Registrant is using the unused filing fees associated with the Prior Post-Effective Amendment to offset the filing fee payable in connection with this filing.